Korean J Thorac Cardiovasc Surg.  2016 Aug;49(4):280-286. 10.5090/kjtcs.2016.49.4.280.

Extracorporeal Life Support in Patients with Hematologic Malignancies: A Single Center Experience

• Choi KB
• Kim HW
• Jo KH
• Kim DY
• Choi HJ
• Hong SB

• KMID: 2348909
• DOI: http://doi.org/10.5090/kjtcs.2016.49.4.280

Abstract

BACKGROUND
Extracorporeal life support (ECLS) in patients with hematologic malignancies is considered to have a poor prognosis. However, to date, there is only one case series reported in the literature. In this study, we compared the in-hospital survival of ECLS in patients with and without hematologic malignancies.
METHODS
We reviewed a total of 66 patients who underwent ECLS for treatment of acute respiratory failure from January 2012 to December 2014. Of these patients, 22 (32%) were diagnosed with hematologic malignancies, and 13 (59%) underwent stem cell transplantation before ECLS.
RESULTS
The in-hospital survival rate of patients with hematologic malignancies was 5% (1/22), while that of patients without malignancies was 26% (12/46). The number of platelet transfusions was significantly higher in patients with hematologic malignancies (9.69±7.55 vs. 3.12±3.42 units/day). Multivariate analysis showed that the presence of hematologic malignancies was a significant negative predictor of survival to discharge (odds ratio, 0.07; 95% confidence interval, 0.01-0.79); p=0.031).
CONCLUSION
ECLS in patients with hematologic malignancies had a lower in-hospital survival rate, compared to patients without hematologic malignancies.

Keyword

Extracorporeal membrane oxygenation; Acute respiratory distress syndrome (ARDS); Hematology

MeSH Terms

Extracorporeal Membrane Oxygenation
Hematologic Neoplasms*
Hematology
Humans
Multivariate Analysis
Platelet Transfusion
Prognosis
Respiratory Insufficiency
Stem Cell Transplantation
Survival Rate